Genomics plc is a genome analysis company formed in 2014 by four leading scientists at the University of Oxford, including Professors Peter Donnelly (then Director of the Wellcome Centre for Human Genetics) and Gil McVean (Director of Oxford’s Big Data Institute). The company’s vision is to use genomic insights to transform the drug discovery process. The company has built a sophisticated suite of analysis tools that leverage machine learning and AI, and has assembled a companion genomic dataset of 100 billion data points. This dataset, which spans an extensive range of human phenotypes, combined with Genomics plc’s unique algorithmic engine, enables powerful insights into the relationship between genetic variation and health outcomes—and allows for the identification and validation of genes and gene pathways amenable to therapeutic drug targeting. Backed by some of the leading investors in life sciences, Genomics has an expert cross-disciplinary team of over 40 people, primarily scientists and software engineers, with offices in Oxford and Cambridge UK.
Foresite Capital believes that Genomics plc will accelerate drug discovery for patients in the UK and around the world.
Foresite Capital believes that Genomics plc will accelerate drug discovery for patients in the UK and around the world.
Location: United Kingdom, England, Oxford
Total raised: $84.53M
Investors 5
Date | Name | Website |
- | Foresite C... | foresiteca... |
- | F-Prime Ca... | fprimecapi... |
- | Oxford Uni... | innovation... |
- | Oxford Sci... | oxfordscie... |
- | Eight Road... | eightroads... |
Funding Rounds 3
Date | Series | Amount | Investors |
08.01.2024 | - | $44.48M | - |
01.03.2021 | - | $30M | - |
10.12.2018 | Series B | $10.05M | - |
Mentions in press and media 13
Date | Title | Description |
16.07.2024 | Genomics plc Expands Drug Discovery Collaboration with Vertex | What You Should Know: –Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals Incorporated (Vertex) (... |
30.04.2024 | Genomics plc & GSK Partner to Optimize Clinical Trials with Genetic Risk Testing | What You Should Know: – Genomics plc, a leader in polygenic risk score (PRS) technology, and pharmaceutical giant GSK inks a new collaboration to explore the potential of PRS for optimizing clinical trial design. – The innovative approach c... |
09.04.2024 | MassMutual Leverages Genomics for Personalized Risk Assessments | What You Should Know: Genomics plc (Genomics), a healthcare company transforming health through the power of genomics, and MassMutual, a leading mutual life insurance company in the United States, today announced the next phase of their inn... |
19.03.2024 | Almaden Genomics and Elucidata Pair g.nome® with Polly | - |
08.01.2024 | UK start-up Genomics raises £35mn for advanced genetic testing | - |
01.09.2021 | The U.K. Genomics Startups Changing The Future Of Healthcare Forever | Genomics: the future of healthcare getty |
01.03.2021 | Genomics PLC Completes Oversubscribed $30M Funding Round | - |
09.10.2020 | Brett Zbar to lead life sciences investing at General Atlantic; Michael Kavanaugh plans retirement as CytomX promotes Genentech vet Marcia Belvin | Brett Zbar → Growth equity firm General Atlantic has reeled in Brett Zbar as managing director to lead its new life sciences focus. Zbar hops aboard from Foresite Capital where he served as managing director and advised o... |
10.12.2018 | Genomics plc Announces second close of Series B financing, raising a further £8m, bringing the total round to £33m | - |
05.09.2018 | Genomics Closes £25M Series B Financing | Genomics plc, an Oxford, UK-based data science company specializing in the use of human genetic information to improve drug development, closed a £25m Series B financing. The round was led by Vertex Pharmaceuticals with participation from I... |
Show more